RBC Initiates Attovia Therapeutics at Outperform, Speculative Risk With $45 Price Target

Citi analyst Yigal Nochomovitz maintained a Buy rating on Attovia Therapeutics (ATTO) with a $30 target, while Morgan Stanley's Chris Quintero reiterated a Buy on Navan (NAVN) with a $33 target. Both stocks have Strong Buy consensus ratings and significant upside potential according to analysts.

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.

Morgan Stanley initiated coverage on Attovia Therapeutics with an Overweight rating. Leerink Partners also started coverage with an Outperform rating and a $52 price target. The stock has seen a 5-day change of 20.70 USD, a 1st Jan change of -3.54%, and a year-to-date change of -0.48%.

Citigroup initiated coverage on Attovia Therapeutics with a Buy rating and a $30 price target. The company's stock is currently trading at $20.49, down 1.01% on the day and 2.33% over the past year. Morgan Stanley also initiated coverage with an Overweight rating.

Attovia filed an amended S-1 for an upsized IPO raising about $265.1 million in net proceeds, up from roughly $182.4 million earlier. Funds will support two Phase II trials starting in H1 2027 for ATTO-1310, an engineered biologic targeting IL-31 for chronic pruritic diseases. The filing cites Phase Ib results and prior funding rounds.